[CAS NO. 180064-38-4] Minodronicacid
PRODUCTS SPECIFICATIONS [180064-38-4]
DESCRIPTION [180064-38-4]
Overview
| MDL | MFCD00890772 |
|---|---|
| Molecular Weight | 322.15 |
| Molecular Formula | C9H12N2O7P2 |
| SMILES | OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2C=CC=CN21 |
Summary
IC50 & Target
P2X2/3 [2]
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00965978 | Astellas Pharma Inc|Ono Pharma USA Inc |
Osteoporosis|Osteoporosis, Postmenopausal|Bone Diseases
|
July 2009 | Phase 1 |
| NCT00212628 | Ono Pharmaceutical Co. Ltd|Astellas Pharma Inc |
Involutional Osteoporosis
|
June 2004 | Phase 3 |
| NCT00794443 | Astellas Pharma Inc|Ono Pharmaceutical Co. Ltd |
Osteoporosis|Bone Loss, Age-Related
|
November 2008 | Phase 2|Phase 3 |
| NCT02295436 | Wuhan Union Hospital, China |
Osteoporosis
|
August 2014 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 5 mg/mL ( 15.52 mM ; Need ultrasonic and warming)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.1041 mL | 15.5207 mL | 31.0414 mL |
| 5 mM | 0.6208 mL | 3.1041 mL | 6.2083 mL |
| 10 mM | 0.3104 mL | 1.5521 mL | 3.1041 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (6.21 mM); Clear solution; Need ultrasonic
References
- [1] Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95(10):1354-61.
- [2] Tanaka M, et al. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors. J Bone Miner Metab. 2018 Jan;36(1):54-63.
Synonyms